Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: South Med J. 2011 Dec;104(12):811–818. doi: 10.1097/SMJ.0b013e31823a8879

Table 3.

Morbidities and Bivariate Associations with Guideline Concordant Colorectal Cancer Screening

Morbidity Colonoscopy
screening
(n = 1,147*)
Any guideline
concordant
screening
(n = 1,134*)

N % Subjects
with
morbidity
N %
Screened
N %
Screened
None 87 7.9 86 50.0§ 85 56.5§
Arthritis 707 61.5 703 62.7 695 69.1
Asthma 224 19.5 220 63.2 219 70.8
Alcohol or drug abuse 25 2.2 25 68.0 24 75.0
Cancer 193 16.8 192 70.3 191 74.4§
Chronic lung disease 162 14.1 161 60.3 159 67.9
Dementia/Alzheimer’s 11 1.0 11 72.7 11 72.7
Depression 361 31.4 360 64.7 356 71.6§
Diabetes 252 21.9 252 59.5 250 68.4
Heart disease 290 25.7 290 66.6§ 287 76.0
Hypertension 682 59.3 680 62.1 674 68.3
Kidney disease 85 7.4 85 67.1 84 77.4§
Liver conditions 59 5.1 59 72.9 59 81.4§
Movement disorders 28 2.4 28 53.6 28 60.7
Stroke 77 7.7 76 73.7§ 75 82.7
Ulcers, heart burn, chronic bowel problems 434 37.7 430 68.6 426 75.4
*

Number of observations varies due to sporadically missing data.

Percentage of respondents who reported a guideline-concordant screening.

Number of respondents who reported having no morbidities or a given condition.

§

Statistically significant difference in screening among subjects with a morbidity (in addition to others) versus subjects without such morbidity using a chi-square test of independence or Fisher’s exact, p < 0.05.

Statistically significant difference, p < 0.01.